Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 479-940-2 | CAS number: 613246-75-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: Expert statement
- Adequacy of study:
- key study
- Study period:
- 2013
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Expert statement, no study available
- Principles of method if other than guideline:
- Expert statement
- Details on absorption:
- All toxicokinetic analyses have to consider that Sika Hardener LJ is designed to rapidly react upon contact with water. Further, the hydrolysis reaction is catalysed in an acid environment. Sika Hardener LJ is a reaction mixture of poiyaldimine, with varying chain length. Calculated logPow values and water solubility for Sika Hardener LJ range from 13.67 to 12.96 and from 2.1E-10 mg/L to 5.6E-13 mg/L, respectively.
The estimated partition coefficient indicates that the compound is not likely to penetrate skin. However, even if dermally absorbed, its toxicity is very low. Although no acute dermal toxicity study was carried out, the compound was assessed in a skin irritation and skin sensitization study. The skin irritation study used rabbits and no local effects or systemic toxicity was noted, following topical application of Sika Hardener LJ. A guinea pig maximisation test did not reveal any signs of toxicity either and the compound was classified a non-sensitiser.
Furthermore, the aldehyde hydrolysis product did not cause any systemic toxicity, following dermal application (LD50 > 2000 mg/kg bw) nor did any of the polyamines formed (LD50 > 2000 mg/kg bw, BASF correspondence and lUCLID-data). Due to its high reactivity and limited stability in water-based systems, orally ingested Sika Hardener LJ will undergo spontaneous hydrolysis upon reaching the stomach, especially as the
hydrolysis reaction is acid catalysed. The portion of Sika Hardener LJ not hydrolysed immediately will, most probably, not solubilize in the stomach. Consequently, Sika Hardener LJ is not likely to cross GI-tract membranes. Taken together, absorption of Sika Harter LJ and consequently bioavailability are highly unlikely.
The products of Sika Hardener LJ decomposition are the aldehyde 2,2-dimethyI-3-lauroyloxy- propanal and respective polyamine (Polyetheramine D 230). The aldehyde is not stable in water-based systems and further degrades forming carbonic acid and several short-chain polar compounds. The polyamines formed might also be transformed further, most likely in enzyme catalyzed metabolism. Even though the degradation products might be absorbed and become bioavailable, they are of low toxicity. - Details on excretion:
- Any polyamines formed by hydrolysis of Sika Hardener LJ that reach the body's systemic circulation are probably either excreted in unchanged form or metabolised by the cytochrome P450 system or by amine oxidases. Phase I metabolism of polyamines is followed by further conjugation of degradation products in phase II metabolism, possibly rendering molecules even more polar. Likely conjugation compounds are glycine and glutamine, preceding the metabolites eventual elimination in urine or bile.
Toxicokinetic assessment of hexamethylenediamine, used as a model compound, revealed that the amine is rapidly distributed systemically following i.v. administration to rats, and completely excreted within 72 hours, via urine (47 %), faces (27 %) and respiration (20 %). Similar excretion can be assumed for all polyamine degradation products. Excretion analysis in humans following oral administration, using the same model compound hexamethylenediamine, revealed that more than 90 % is eliminated in urine, during the first 10 hours post administration, either unchanged or metabolised to 6-aminohexanoic acid. A human inhalation study revealed that 90 % were eliminated within the first 28 hours following exposure to 25 µg/m3. In a second human inhalation study and exposure to 30 µg/m3, 90 % hexamethylenediamine was eliminated via the urine within the first three hours. For both human inhalation studies the renal half-life of hexamethylenediamine was determined to be 1.4 hours and 1.2 hours, respectively. A similar excretion pattern can be assumed for all
polyamine degradation products in humans. - Details on metabolites:
- One of the most important pathway of aldehyde metabolism is oxidation to carboxylic acids by aldehyde dehydrogenases (Vasiliou et al.t 2000). The enzymes involved in these detoxification reactions most probably belong to the category of aldehyde dehydrogenases, known to be relatively substrate unspecific, but effective in protecting organisms from potentially harmful xenobiotics (Sladek, 2003). Other phase I metabolic reactions may include cytochrome P450 mediated transformations such as aldehyde reductions or aldehyde scissions. Following phase I metabolic reactions or chemical decomposition, the formed metabolites are rendered more polar by phase II metabolism. Most likely the carboxylic acid metabolites are ultimately conjugated with glycine or glutamine and excreted in urine or bile.
It is unlikely that metabolism will render the parent compound or its degradation products more toxic. This assumption is supported by results obtained in an in vitro Ames test and a chromosome aberration test. In both assays no significant increases in toxicity were noted, in the presence of a rodent microsomal S9-fraction. This clearly indicates that formation of reactive metabolites is rather unlikely. - Conclusions:
- Based on the reactive nature of Sika Hardener LJ and its limited stability in water-based systems, bioaccumulation is not likely to occur. Orally consumed hardener is most rapidly hydrolysed to aldehyde and polyamine, with the reaction being acid catalysed. Even though the degradation products might be absorbed and become bioavailable, toxicity is low and bioconcentration unlikely. Absorbed or bioavailable degradation products are probably excreted, either in original form or further metabolized, prior to elimination via urine or bile. Formation of toxic metabolites is usually, based on the results of the sub-acute toxicity study and two in vitro studies using isolated S9 fractions.
Reference
Description of key information
Based on the reactive nature of Sika Hardener LJ and its limited stability in water-based systems, bioaccumulation is not likely to occur. Orally consumed hardener is most rapidly hydrolysed to aldehyde and polyamine, with the reaction being acid catalysed. Even though the degradation products might be absorbed and become bioavailable, toxicity is low and bioconcentration unlikely. Absorbed or bioavailable degradation products are probably excreted, either in original form or further metabolized, prior to elimination via urine or bile. Formation of toxic metabolites is usually, based on the results of the sub-acute toxicity study and two in vitro studies using isolated S9 fractions.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
All toxicokinetic analyses have to consider that Sika Hardener LJ is designed to rapidly react upon contact with water. Further, the hydrolysis reaction is catalysed in an acid environment. Sika Hardener LJ is a reaction mixture of poiyaldimine, with varying chain length. Calculated logPow values and water solubility for Sika Hardener LJ range from 13.67 to 12.96 and from 2.1E-10 mg/L to 5.6E-13 mg/L, respectively.
The estimated partition coefficient indicates that the compound is not likely to penetrate skin. However, even if dermally absorbed, its toxicity is very low. Although no acute dermal toxicity study was carried out, the compound was assessed in a skin irritation and skin sensitization study. The skin irritation study used rabbits and no local effects or systemic toxicity was noted, following topical application of Sika Hardener LJ. A guinea pig maximisation test did not reveal any signs of toxicity either and the compound was classified a non-sensitiser.
Furthermore, the aldehyde hydrolysis product did not cause any systemic toxicity, following dermal application (LD50 > 2000 mg/kg bw) nor did any of the polyamines formed (LD50 > 2000 mg/kg bw, BASF correspondence and lUCLID-data). Due to its high reactivity and limited stability in water-based systems, orally ingested Sika Hardener LJ will undergo spontaneous hydrolysis upon reaching the stomach, especially as the
hydrolysis reaction is acid catalysed. The portion of Sika Hardener LJ not hydrolysed immediately will, most probably, not solubilize in the stomach. Consequently, Sika Hardener LJ is not likely to cross GI-tract membranes. Taken together, absorption of Sika Hardener LJ and consequently bioavailability are highly unlikely.
The products of Sika Hardener LJ decomposition are the aldehyde 2,2-dimethyI-3-lauroyloxy- propanal and respective polyamine (Polyetheramine D 230). The aldehyde is not stable in water-based systems and further degrades forming carbonic acid and several short-chain polar compounds. The polyamines formed might also be transformed further, most likely in enzyme catalyzed metabolism. Even though the degradation products might be absorbed and become bioavailable, they are of low toxicity.
One of the most important pathway of aldehyde metabolism is oxidation to carboxylic acids by aldehyde dehydrogenases (Vasiliou et al.t 2000). The enzymes involved in these detoxification reactions most probably belong to the category of aldehyde dehydrogenases, known to be relatively substrate unspecific, but effective in protecting organisms from potentially harmful xenobiotics (Sladek, 2003). Other phase I metabolic reactions may include cytochrome P450 mediated transformations such as aldehyde reductions or aldehyde scissions. Following phase I metabolic reactions or chemical decomposition, the formed metabolites are rendered more polar by phase II metabolism. Most likely the carboxylic acid metabolites are ultimately conjugated with glycine or glutamine and excreted in urine or bile.
It is unlikely that metabolism will render the parent compound or its degradation products more toxic. This assumption is supported by results obtained in an in vitro Ames test and a chromosome aberration test. In both assays no significant increases in toxicity were noted, in the presence of a rodent microsomal S9-fraction. This clearly indicates that formation of reactive metabolites is rather unlikely.
Any polyamines formed by hydrolysis of Sika Hardener LJ that reach the body's systemic circulation are probably either excreted in unchanged form or metabolised by the cytochrome P450 system or by amine oxidases. Phase I metabolism of polyamines is followed by further conjugation of degradation products in phase II metabolism, possibly rendering molecules even more polar. Likely conjugation compounds are glycine and glutamine, preceding the metabolites eventual elimination in urine or bile.
Toxicokinetic assessment of hexamethylenediamine, used as a model compound, revealed that the amine is rapidly distributed systemically following i.v. administration to rats, and completely excreted within 72 hours, via urine (47 %), faces (27 %) and respiration (20 %). Similar excretion can be assumed for all polyamine degradation products. Excretion analysis in humans following oral administration, using the same model compound hexamethylenediamine, revealed that more than 90 % is eliminated in urine, during the first 10 hours post administration, either unchanged or metabolised to 6-aminohexanoic acid. A human inhalation study revealed that 90 % were eliminated within the first 28 hours following exposure to 25 µg/m3. In a second human inhalation study and exposure to 30 µg/m3, 90 % hexamethylenediamine was eliminated via the urine within the first three hours. For both human inhalation studies the renal half-life of hexamethylenediamine was determined to be 1.4 hours and 1.2 hours, respectively. A similar excretion pattern can be assumed for all polyamine degradation products in humans.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.